What is Relmada Therapeutics, Inc.'s financing cash flow?

Relmada Therapeutics, Inc. (RLMD) reported financing cash flow of $156.57M in Q1 2026.

What is the long-term trend for Relmada Therapeutics, Inc.'s financing cash flow?

Over 2 years (2021 to 2023), Relmada Therapeutics, Inc.'s financing cash flow has grown at a -97.7% compound annual growth rate (CAGR), from $187.94M to -$98.46K.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Relmada Therapeutics, Inc. RLMD Financing Cash Flow

Financing Cash Flow at other companies

Johnson & JohnsonJNJ

$530M-94.9%

Merck & Co.MRK

-$2.98B+48.2%

CG OncologyCGON

$393M+87,233%

ArvinasARVN

-$100K0.0%

Nuvectis Pharma, Inc.NVCT

$7K-100.0%

Replimune GroupREPL

$10.45M-93.3%

Other financials

Income statement

See full

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Balance sheet

See full

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Cash flow

See full

Operating cash flow-$15.1M+16.6%

Valuation

See full

Market cap$677.17M+2,907%

Returns & leverage

See full

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s financing cash flow?: Relmada Therapeutics, Inc. (RLMD) reported financing cash flow of $156.57M in Q1 2026.
What is the long-term trend for Relmada Therapeutics, Inc.'s financing cash flow?: Over 2 years (2021 to 2023), Relmada Therapeutics, Inc.'s financing cash flow has grown at a -97.7% compound annual growth rate (CAGR), from $187.94M to -$98.46K.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.